Your session is about to expire
← Back to Search
Other
Etrumadenant + Zimberelimab for Sarcoma
Phase 2
Recruiting
Led By Evan Rosenbaum, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
Study Summary
This trial will test the effectiveness of a drug combo to treat advanced dedifferentiated liposarcoma, which has come back, spread, or is unresectable.
Who is the study for?
Adults with advanced dedifferentiated liposarcoma that's inoperable, recurrent, or has spread to other parts of the body can join this trial. They should have tried other treatments without success and be in good health otherwise, with no severe allergies to certain antibodies or active infections like hepatitis or tuberculosis.Check my eligibility
What is being tested?
The study is testing a combination of two drugs: Etrumadenant and Zimberelimab. It aims to see if they work together as an effective treatment for this type of sarcoma. Participants will receive both medications and their effects on the cancer will be monitored.See study design
What are the potential side effects?
Possible side effects include immune system reactions that might cause inflammation in various organs, allergic responses to the drug infusion, fatigue, potential liver function changes, blood-related issues such as low counts which could increase infection risk.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Response Rate
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants With Dedifferentiated Liposarcoma/DDLPSExperimental Treatment2 Interventions
Participants will have a diagnosis of recurrent or metastatic Dedifferentiated Liposarcoma/DDLPS
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etrumadenant
2018
Completed Phase 1
~130
Zimberelimab
2018
Completed Phase 1
~50
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,873 Total Patients Enrolled
70 Trials studying Sarcoma
13,742 Patients Enrolled for Sarcoma
Evan Rosenbaum, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
332 Total Patients Enrolled
3 Trials studying Sarcoma
332 Patients Enrolled for Sarcoma
Sandra D'Angelo, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
192 Total Patients Enrolled
3 Trials studying Sarcoma
150 Patients Enrolled for Sarcoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have active cancer spread to my brain or spinal cord.I am currently being treated for another cancer that is not related.I have been treated with PD-1 or PD-L1 inhibitors before.I have HIV with specific CD4+ T-cell counts or opportunistic infections.My condition is an advanced liposarcoma that cannot be surgically removed.I have had an active tuberculosis infection in the past.I have been treated with drugs targeting the adenosine pathway.I have an active hepatitis B or C infection.I am fully active or able to carry out light work.My blood tests for organ function are within normal ranges.I cannot take pills due to my stomach or intestinal problems.My current medications do not interact with etrumadenant.I have had previous treatments for my condition.I am 18 years old or older.I haven't had recent cancer treatments or major surgery.I do not have any uncontrolled illnesses or heart failure symptoms in the last 6 months.My cancer came back after surgery to remove the initial tumor.I have not needed treatment for an autoimmune disease in the last 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Participants With Dedifferentiated Liposarcoma/DDLPS
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the U.S. Food & Drug Administration given clearance to use Participants With Dedifferentiated Liposarcoma/DDLPS?
"Although no efficacy data is available, participants with dedifferentiated liposarcoma/DDLPS were rated a 2 due to the existence of safety-related clinical evidence."
Answered by AI
What is the geographic scope of this clinical trial's implementation?
"This trial is currently running at 7 clinical sites, that are spread out between Middletown, Montvale and Commack as well as other cities. If you choose to participate in the study it is advised to pick the most convenient location for yourself so as to reduce any transportation needs."
Answered by AI
Are there any remaining vacancies for participants in this medical trial?
"Indeed, clinicaltrials.gov shows that the study is currently recruiting. It was posted on May 23rd 2023 and updated then too; it requires 25 patients to volunteer from 7 sites."
Answered by AI
How many volunteers are being enlisted for this clinical experiment?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial is actively seeking 25 participants from seven different clinics since its inception on May 23rd, 2023 and most recent update of the same date."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger